The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke
Authors
- Fei Fei (ORCID: https://orcid.org/0000-0002-9246-9775)
- Yuxin Hong (ORCID: https://orcid.org/0009-0007-7955-0046)
- Luhua Wei (ORCID: https://orcid.org/0000-0003-3056-1573)
- Hengwen Song
- Lei Huang (ORCID: https://orcid.org/0000-0001-9464-8577)
- Juan Li (ORCID: https://orcid.org/0000-0001-8320-2406)
- Zhiyou Chen (ORCID: https://orcid.org/0000-0002-9265-5068)
- Runbin Sun (ORCID: https://orcid.org/0000-0001-5632-0431)
- Haoyi Yang (ORCID: https://orcid.org/0009-0002-7361-3425)
- Yuwen Zhang (ORCID: https://orcid.org/0009-0001-2340-437X)
Institutions
- Nanjing University of Chinese Medicine (CN)
- China Pharmaceutical University (CN)
- Nanjing Drum Tower Hospital (CN)
- Buchang Pharma (China) (CN)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1080/13543784.2024.2430200
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00